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DOI 10.1016/j.chembiol.2007.03.005Diabetes mellitus is a progressive dis-
order that prevents the body from ef-
fectively regulating blood glucose
levels. Patients with Type II diabetes
either do not make enough insulin
or become resistant to it. In contrast,
Type I diabetes, otherwise known as
juvenile diabetes, is an autoimmune
disease in which an individual loses
the ability to produce insulin.
The symptoms associated with dia-
betes were recognized in ancient
times. However, only in the late 19th
century was the relationship between
diabetes and the pancreas discov-
ered. About 40 years later, Nicolae
Paulescu reported the first isolation
of insulin, the active hormone that is
secreted by the pancreas. Frederick
Banting and Charles Best followed
a few months later and subsequently
shared a Nobel Prize with John Ma-
cleod. The distinction between Type I
and Type II diabetes was only made
in 1936.
Normally, body glucose is regulated
by secretions of hormones from both
aandbcells in thepancreas.Theacells
secrete a hormone, glucagon, which
promotes breakdown of glycogen in
the liver. b cells secrete insulin, which
induces uptake of glucose into cells,
primarily muscle, fat, and liver. Incretin
hormones GLP-1 (glucogen-like pep-
tide) and GIP (glucose-dependent in-
sulinotropic polypeptide) secreted in
the gut modify the activity of both cell
types. GLP-1 and GIP enhance the re-
lease of insulin by b cells when glucose
levels go up. GLP-1 signals a cells to
suppress glucagon release.
In many diabetic patients, the nor-
mal response to glucose and produc-
tion of insulin is disrupted. Insulin-
resistant diabetics typically have high
levels of both glucose and insulin.
a cells lose glucose sensitivity, releas-
ing too much glucagon when glucose
is normal or high. As the disease prog-
resses, the b cells become exhausted
from overproduction of insulin and
eventually die. It is estimated that by
the time diabetes is diagnosed, 50%
of the b cells have already died. The
individual becomes dependent on out-
side insulin to regulate blood sugar.
The physiological toll of poorly man-
aged blood sugar is drastic over time;
individuals can experience retinal
damage, circulatory problems, nerve
damage leading to amputations; and
kidney disease.
Genes Load the Gun. Lifestyle
Pulls the Trigger
Asglobal obesity rates rise, the number
of people developing Type II diabetes
is skyrocketing. The World Health
Organization estimates that 180million
people worldwide have diabetes, and
that the number will double by 2030.
TheAmericanDiabetesAssociationas-
serts that approximately 7%of theU.S.
population has diabetes. While diabe-
tes usually strikes adults over 40, the
number of children developing Type II
diabetes seems to be rising rapidly as
well. However, opportunity emerges
from crisis, and diabetes research pro-
grams both in academic institutions
and drug companies are flourishing.
Type II diabetes runs in families; it
has a genetic component. As only
15%–20% of the people who become
obese become diabetic, the implica-
tion is that a genetic predisposition is
triggered by obesity and inactivity,
which are lifestyle choices. (Another
explanation is defective b cells.) ‘‘Most
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cal agents,’’ said Dr. Christopher Saudek, professor of Endo-
crinology andMetabolism at Johns HopkinsMedical School.Chemistry & Biology 14, March 2007 ªpeople with type II diabetes will need
pharmacological agents,’’ said Dr.
Christopher Saudek, professor of en-
docrinology and metabolism at Johns
Hopkins Medical School. ‘‘In the early
stages of type II diabetes, you may be
able to control the diabetes with diet
and activity. Most people won’t be
able to go a lifetime taking just one
kind of pill, because the ability of the
pancreas to make insulin is progres-
sivelydeteriorating inType II diabetes.’’
Existing Treatments Leave Room
for Improvement
The tried and true drugs targeting dia-
betes all have drawbacks. For exam-
ple, sulfonylureas and the newer gliti-
nides induce the pancreas to secrete
insulin but can lead to hypoglycemia
and weight gain. a-Glucosidase inhib-
itors prevent absorption of carbohy-
drates, but cause unpleasant gastroin-
testinal symptoms. Thiazolidinediones
(TZDs) increase peripheral sensitivity
to insulin but are unsuitable for cardiac
patients and can cause fluid retention
and weight gain.
While these drugs ameliorate symp-
toms, they do not arrest progression of
the disease and they also stopworking
after a certain point. ‘‘The ideal dream
drug would both reverse the disease
and prevent its progression,’’ said Dr.
Joel Habener, chief of the Laboratory
of Molecular Endocrinology at Massa-
chusetts General Hospital, ‘‘by stimu-
lating the b cells and at the same
time increase their lifespan.’’
Discovery of Incretin Mimetics
A major breakthrough in diabetes re-
search occurred in the 1970s with the
discovery by Habener of the GLP-1
system that regulates release of insu-
lin, which occured in the course of re-
searching how the pancreas worked
through the examination of marble-
sized pancreases of angler fish.
Dr. Jens Holst, of the department of
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Dr. Michael Nauck of Ruhr-University
in Germany, showed how GLP-1 func-
tioned in humans.
GLP-1 is a hormone derived from the
proglucagongeneand is secreted from
the intestine after meals. It stimulates
b cell insulin secretion in response to
glucose, but it doesn’t increase insulin
blood levels at low glucose concentra-
tions. GLP-1 also functions as an ap-
petite suppressant, causing patients
to lose weight. Unfortunately, GLP-1
was unsuitable as a drug due to its
fleeting half-life; it is rapidly degraded
by theenzymedipeptidyl peptidase-IV.
Habener’s research opened the
door towhat became incretinmimetics
(and to later research on developing
DPP-4 inhibitors that stimulate internal
incretin hormones), a new class of glu-
coregulatory hormones that may not
be the ‘‘dream’’ drugs but which are
incrementally closer. Later research
developed classes of DPP-IV enzyme
inhibitors to prolong the action of en-
dogenous incretin hormones.
Drooling over Gila Monsters
In the 1980s, John Eng, a researcher
at the Bronx Veterans Administration
MedicalCenter,was studyingpeptides
produced in the saliva of the gila mon-
ster (Heloderma suspectum), a lizard
that eats only three or four times a
year. He realized that a peptide iso-
lated from the lizard saliva, exendin-4,
was similar to human GLP-1 but was
longer livedand loweredbloodglucose
in a mouse model. As the story goes,
scientists at San Diego-based Amylin
(http://www.amylin.com) licensed it
from Eng and developed Exenatide,
a long-lasting, 39 amino acid synthetic
analog of GLP-1. Now marketed with
Eli Lilly and Company as Byetta, this
GLP-1 agonist stimulates the pancreas
to produce insulin in response to rising
blood sugar levels and inhibits the liver
from breaking down glycogen to re-
lease glucose after meals. Byetta was
approved by the FDA in 2005 for pa-
tients who fail treatments with oral
drugs, and Lilly plans to launch it in
Europe in 2007. It has similar efficacy
to bedtime insulin (without the weight
gain), but it is more expensive.
Another welcome effect of Byetta is
weight loss, according to Dr. Michael236 Chemistry & Biology 14, March 2007Hanley, vice president of discovery
research at Amylin. However, Byetta
must be injected twice daily and its
side effects include nausea and mild
hypoglycemia. Amylin and Alkermes
(http://www.alkermes.com) are code-
veloping Exenatide LAR, a therapeutic
peptide encapsulated in microspheres
for weekly injection. According to Han-
ley, Byetta shows promising results in
restoring b cell mass and function in
laboratory animals, but this effect has
not so far been tested in humans. ‘‘This
is a pretty generally agreed robust re-
sult obtained by multiple labs, particu-
larly in laboratory animals, and anec-
dotally I’ve heard evidence that also
in large animals—that in various types
of induction of damage. Byetta can
restore b cell mass as needed,’’ said
Hanley.
SIMLYN, Amylin’s other lead com-
pound, approved by the FDA in 2002,
is a synthetic amylin analog (pramlin-
tide). Amylin, a hormone ordinarily
cosecreted with insulin by the b cells,
lowers blood sugar, suppresses glu-
cagon secretion, and slows gastric
emptying after meals, causing weight
loss. Pramlintide is linked to insulin-
induced hypoglycemia when used in
conjunction with insulin, as absorption
of carbohydrates is slowed, so the
insulin dosage must be calibrated.
Along with diabetes drugs, Amylin is
developing a portfolio of antiobesity
therapeutics. Positioned as an alterna-
tive to bariatric surgery, the platform
features compounds based on Exena-
tide and SYMLIN used in conjunction
with the fat-derived hormone leptin.
While reducing body weight by around
5% is a welcome side effect of Byetta,
any ensuing antiobesity formulation
would have to sustain a more substan-
tial weight loss without serious side
effects.
Amylin was founded in 1987. The
company now counts 1600 employees
including its sales force and is publicly
traded. Most of Amylin’s current finan-
cial support comes from a collabora-
tion agreement with Lilly to develop
and market Byetta. Amylin reported
total revenue of $510.9 million for
2006, including net product sales of
$474 million. However, like many bio-
techs, it still operates at a loss ($218.9
million in 2006).ª2007 Elsevier Ltd All rights reservedDPP-IV Inhibitors Come
to Market
DPP-IV inhibitors, a new class of oral
antidiabetic medicines working by in-
cretin enhancement, are starting to
be approved by the FDA. Dozens of
companies are now engaged in their
development. DDP-IV inhibitors block
the enzyme dipeptidyl peptidase-IV
that breaks down GLP-1 and GIP,
effectively increasing the circulating
levels of the incretin hormones and
stimulating the pancreas to produce
insulin. The hope is that DPP-IV inhib-
itors will produce fewer side effects
than existing medications. Merck’s
Januvia (sitagliptin, a piperazine deriv-
ative) is a synthetic small molecule in
a once-a-day tablet that was approved
by the FDA in October 2006 for solo
use or in combination therapy.
Merck’s competitor Novartis just
hit a pothole on the road to approval
as the FDA demanded new data on its
investigational drug Galvus (vildaglip-
tin, a cyanopyrrolidine derivative) after
monkeys developed skin lesions dur-
ing testing, delaying approval for at
least a year. The FDA wants additional
tests in patients with impaired kidneys
who would be slower to process the
drug from their system. Galvus is cur-
rently being evaluated by European
regulators.
Other entrants to the DPP-IV sweep-
stakes include saxagliptin (1-cis-4,5-
methanoprolinenitrile) that is now in
late-stage clinical trials conducted
jointly by Bristol Myers Squibb and As-
traZeneca. This lead has also caused
skin lesions in monkeys at high doses.
Takeda’s SYR-322 (a pyrimidine deriv-
ative) is in Phase III trials, and Novo
Nordisk’s Liraglutide, based on Hab-
ener’s work, is in stage III trials.
There are glimmers that these drugs
can reverse b cell destruction, but just
glimmers. There is still no cure for Type
II diabetes. Lifestyle changes remain
the best strategy to stave off its onset
for those with susceptibility. Although
they still need to be field tested in
general use, these new classes of
drugs are promising—and any poten-
tial weight loss derivatives could be
an utter bonanza.
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